A newnational online community provides support for individuals affected by Waldenström’s Macroglobulinemia.
Boston, MA & Sun Valley, ID – OMNI Health Media (OMNI) announces the launch of an online community for individuals affected by Waldenström’s Macroglobulinemia, a rare, slow-growing type of non-Hodgkin’s lymphoma. Experts from Dana-Farber Cancer Institute will moderate the community, which will provide patients and their loved ones with welcome information and support. This community will be part of the national CancerConnect.com initiative.
OMNI founder and CEO Charles Weaver, MD says, “We are excited to partner with Dana-Farber to offer patients affected by Waldenström’s Macroglobulinemia this valuable resource.” This will be the third CancerConnect community launched by Dana-Farber. Similar programs exist for Dana-Farber patients and for young adults with cancer and their caregivers.
Research increasingly shows that cancer patients seek validation, information, and support via social media. “Online correspondence is especially important to have when dealing with a rare-disease like Waldenström’s Macroglobulinemia, a lymphoplasmacytic lymphoma,” says Chris Patterson, administrative director of the Dana-Farber Bing Center for Waldenström’s Macroglobulinemia. “It is not always easy to find a counselor you trust, or a support group near you, but it is always possible to receive the support you need online where you can chat freely with other people living with Waldenström’s Macroglobulinemia, swap stories, share advice, help one another and even develop new friendships.”
Unlike other social media platforms, CancerConnect allows individuals to interact in a HIPPA-compliant, confidential, safe, and secure environment. As part of this program, members of the community can also participate in more than sixty disease-specific national communities for individuals with similar interests. Cancer-specific groups are available, as well as groups focused on caregiving, health and wellness, clinical trials, insurance, nutrition and survivorship, providing support for anyone affected by a diagnosis of cancer. Together, these communities offer an online destination populated with rich content to support the many ongoing needs of individuals battling cancer.
Currently, more than 15,000 cancer patients are interacting with and supporting each other on the CancerConnect platform, which is now used by Roswell Park Cancer Institute, The Seattle Cancer Care Alliance, Loyola University Medical Center, The Ohio State James Cancer Institute, Memorial Sloan-Kettering Cancer Center, and other leading providers of cancer care. Recently, a similar platform for patients with Rheumatoid Arthritis was launched; www.TheRAConnection.com
Mobocertinib Treatment for Non-Small Cell Lung Cancer with exon 20 Mutations
FDA grants breakthrough therapy status to Mobocertinib for treatment of patients with NSCLC and exon 20 mutations.
Tagrisso® - Standard of Care for EGFR + Non Small Cell Lung Cancer
FLAURA study confirms Tagrisso as best initial treatment of EGFR + NSCLC - learn more about its role in NSCLC management
About OMNI Health Media: OMNI Health Media is a leading specialty publisher of health-related information with an emphasis on cancer, and on line applications and websites specifically for consumers. Established in 1996, OMNI develops and distributes multi-media health education content and programming, with an emphasis on cancer and women’s health. OMNI has developed over 200 websites and supplies educational content and programming to over 2700 physicians for use on cancer center and clinic websites, including CancerConnect.com. OMNI’s award-wining content programs reach over 1 million seekers of cancer information in English, Japanese, and Spanish each month.
About CancerConnect:CancerConnect.com is the leading social network for cancer patients, their friends, and family. This unique online application was developed by OMNI Health Media and combines a robust information platform consisting of current comprehensive information on cancer with a social network. It is populated with rich content to support the many ongoing needs of individuals battling cancer and is comprised of communities of individuals with similar interests in the area of cancer. The CancerConnect application is also available as a fully functional “private label” social network for people with cancer, their caregivers, and others who are interested in staying up-to-date about the set of diseases known as cancer. CancerConnect is used by Memorial Sloan-Kettering Cancer Center, Roswell Park Cancer Inst., The Ohio State James Cancer Inst., the Seattle Cancer Care Alliance and other leading centers. CancerConnect is licensed to hospitals and cancer clinics to enhance their Web sites, improve SEO, and allow cancer patients to be part of a social community without leaving the clinic. Disease-specific groups, as well as groups focused on care giving, health and wellness, and nutrition all exist to provide support for anyone affected by a diagnosis of cancer.
About Dana-Farber Cancer Institute (www.dana-farber.org) Dana-Farber is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute. It provides adult cancer care with Brigham and Women’s Hospital as Dana-Farber/Brigham and Women’s Cancer Center and it provides pediatric care with Boston Children’s Hospital as Dana-Farber/Children’s Hospital Cancer Center. Dana-Farber is the top ranked cancer center in New England, according toU.S. News & World Report, and one of the largest recipients among independent hospitals of National Cancer Institute and National Institutes of Health grant funding.
Follow Dana-Farber on Twitter: @danafarber
Follow Dana-Farber on Facebook: www.facebook.com/danafarbercancerinstitute
Copyright © 2018 CancerConnect. All Rights Reserved.